Atrial Fibrillation - SymptomaticProcedure
What this study is
A two-pronged approach to evaluate long term success of non-paroxysmal ablation when using a:
1. specified low voltage-directed with pulmonary vein isolation (LD+PVI) approach compared to , 2. an approach of pulmonary vein isolation (PVI) alone.
What's being tested
- Radiofrequency ablation
Intervention · PROCEDURE
Ablation procedure to eliminate atrial fibrillation
Study details
- Official title
- Prospective, Multi-center, Randomized, Evaluation Comparing the Protocol Specified Ablation Approach to the Current Standardized Ablation Approach in the Treatment of Non-paroxysmal Atrial Fibrillation.
- Sponsor
- Ohad Ziv
- Conditions
- Atrial Fibrillation - Symptomatic
- Enrolling
- 250 people
- Starts
- 2019-07-14
- Est. completion
- 2027-12-31
- Design
- Double-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 85 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Non-Paroxysmal Atrial Fibrillation.
- Failed or intolerable to at least 1 one antiarrhythmic drug (AAD).
- 18-85 year of age at time of consent.
- Scheduled to undergo a clinically indicated AF ablation procedure.
- Able and willing to comply with all protocol visit requirements.
- Signed Patient Informed Consent (ICF).
- Presence of low voltage in the left atrium on 3-D map during index catheter ablation procedure
You can't join if
- History of prior left-sided catheter or surgical ablation for AF or atypical atrial flutter, including MAZE or mini MAZE.; Prior ablation for typical atrial flutter or left-sided ablation for WPW, AV node reentry tachycardia or focal ectopic atrial tachycardia may be included.
- Uncontrolled heart Failure or NYHA Class IIIb or IV heart failure.
- Ejection Fraction < 0.20.
- Active ventricular tachycardia requiring treatment with catheter ablation or anti-arrhythmic drug within the last 6 months.
- Left atrial size > 60 mm diameter on echocardiogram.
- "Long standing" persistent AF defined as > or = 1 year of continuous atrial fibrillation at the time of enrollment.
- Severe pulmonary hypertension (PAP > 70 mmHg)
- Unstable valvular disease.
- AF secondary to electrolyte imbalance, thyroid disease or reversible non- cardiac cause.
- Poor candidate for general anesthesia.
- Anticipated survival < 1 year.
- MI or CABG within 3 months.
- Left atrial thrombus in pre-procedure imaging within 4 weeks of the ablation procedure.
- Any documented thromboembolic event within 6 months of the ablation procedure.
- Contraindication to anticoagulation.
- Inability to have implantable monitoring device for atrial fibrillation burden with no pre-existing cardiac device that can monitor atrial arrhythmias OR inability to wear external Holter Monitor continuously for 4 weeks.
- Significant congenital anomaly or medical condition that may affect the integrity of study data.
- Women who are pregnant - pregnancy test required if pre-menopausal or non-sterile.
- Active enrollment in another investigational study involving a drug or device.
- Inability to undergo complete voltage mapping in normal sinus rhythm - see intraprocedural protocol.
- Presence of any medical or psychological condition or medical non-compliance history that may adversely impact study outcomes.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openMetroHealth Medical Center
Cleveland, Ohio, United States
- Peter Leo BS, RN · Contact216-778-2714pleo@metrohealth.org
Recruiting
Study team
Sponsor
Ohad Ziv
Study ID IRB17-00025
Principal investigator
Ohad Ziv, MD
MetroHealth System, Ohio
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.